Acting FDA chief vows to shield rare-disease discussions from political influence

Acting FDA Commissioner Kyle Diamantas met with executives from fifteen rare‑disease nonprofit groups and senior agency staff. During the gathering he emphasized a new approach that differs from the previous administration's stance.

Diamantas said the FDA will work to keep political considerations out of rare‑disease policy discussions, aiming to protect scientific integrity and patient interests. The remarks suggest a shift toward greater independence in how the agency handles rare‑disease matters.

The meeting underscores the FDA's ongoing engagement with disease‑specific advocacy groups and signals to the industry that regulatory decisions will be guided by data rather than external pressures.